IDEXX Laboratories Inc (IDXX) stock
IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3036% above fair value
$698.47+8.23 (+1.19%)
Close on Nov 18, 2026Market cap $55.03BP/E 49.1Yield –
IDEXX Laboratories operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
IDEXX Laboratories's operating cash flow for the twelve months ending Jun 30, 2026 was $1.37B, up 51.4% year over year. For fiscal 2025 it was $1.18B, up 27.2% from the year before. Over ten years it grew 18.2% a year on average. The highest annual figure on record is $1.18B in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.18B | +27.2% |
| FY2024 | Dec 31, 2024 | $929.00M | +2.5% |
| FY2023 | Dec 31, 2023 | $906.51M | +66.9% |
| FY2022 | Dec 31, 2022 | $542.98M | -28.1% |
| FY2021 | Dec 31, 2021 | $755.55M | +16.6% |
| FY2020 | Dec 31, 2020 | $648.06M | +41.1% |
| FY2019 | Dec 31, 2019 | $459.16M | +14.8% |
| FY2018 | Dec 31, 2018 | $400.08M | +7.2% |
| FY2017 | Dec 31, 2017 | $373.28M | +10.1% |
| FY2016 | Dec 31, 2016 | $338.94M | +52.8% |
| FY2015 | Dec 31, 2015 | $221.80M | -6.0% |
| FY2014 | Dec 31, 2014 | $235.85M | -4.1% |
| FY2013 | Dec 31, 2013 | $246.00M | +10.6% |
| FY2012 | Dec 31, 2012 | $222.41M | +2.1% |
| FY2011 | Dec 31, 2011 | $217.91M | +21.9% |
| FY2010 | Dec 31, 2010 | $178.83M | +2.2% |
| FY2009 | Dec 31, 2009 | $174.95M | +22.1% |
| FY2008 | Dec 31, 2008 | $143.31M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $347.16M | +86.9% |
| Q1 FY2026 | Mar 31, 2026 | $266.25M | +11.9% |
| Q4 FY2025 | Dec 31, 2025 | $355.76M | +35.8% |
| Q3 FY2025 | Sep 30, 2025 | $402.34M | +82.8% |
| Q2 FY2025 | Jun 30, 2025 | $185.74M | -25.2% |
| Q1 FY2025 | Mar 31, 2025 | $237.96M | +19.8% |
| Q4 FY2024 | Dec 31, 2024 | $262.03M | +4.9% |
| Q3 FY2024 | Sep 30, 2024 | $220.08M | -19.2% |
| Q2 FY2024 | Jun 30, 2024 | $248.31M | +24.0% |
| Q1 FY2024 | Mar 31, 2024 | $198.59M | +8.0% |
| Q4 FY2023 | Dec 31, 2023 | $249.85M | +44.1% |
| Q3 FY2023 | Sep 30, 2023 | $272.43M | +44.1% |
| Q2 FY2023 | Jun 30, 2023 | $200.31M | +204.2% |
| Q1 FY2023 | Mar 31, 2023 | $183.91M | +60.3% |
| Q4 FY2022 | Dec 31, 2022 | $173.43M | -17.4% |
| Q3 FY2022 | Sep 30, 2022 | $189.00M | +1.0% |
| Q2 FY2022 | Jun 30, 2022 | $65.85M | -71.9% |
| Q1 FY2022 | Mar 31, 2022 | $114.71M | -7.8% |
| Q4 FY2021 | Dec 31, 2021 | $209.96M | -4.1% |
| Q3 FY2021 | Sep 30, 2021 | $187.21M | -3.1% |
| Q2 FY2021 | Jun 30, 2021 | $233.96M | +12.4% |
| Q1 FY2021 | Mar 31, 2021 | $124.42M | +346.4% |
| Q4 FY2020 | Dec 31, 2020 | $218.93M | +40.9% |
| Q3 FY2020 | Sep 30, 2020 | $193.12M | +46.0% |
| Q2 FY2020 | Jun 30, 2020 | $208.14M | +51.8% |
| Q1 FY2020 | Mar 31, 2020 | $27.87M | -18.9% |
| Q4 FY2019 | Dec 31, 2019 | $155.41M | +14.6% |
| Q3 FY2019 | Sep 30, 2019 | $132.27M | +19.5% |
| Q2 FY2019 | Jun 30, 2019 | $137.10M | +15.4% |
| Q1 FY2019 | Mar 31, 2019 | $34.38M | -1.5% |
| Q4 FY2018 | Dec 31, 2018 | $135.65M | +12.0% |
| Q3 FY2018 | Sep 30, 2018 | $110.71M | +0.0% |
| Q2 FY2018 | Jun 30, 2018 | $118.83M | +7.8% |
| Q1 FY2018 | Mar 31, 2018 | $34.90M | +11.6% |
| Q4 FY2017 | Dec 31, 2017 | $121.13M | +20.2% |
| Q3 FY2017 | Sep 30, 2017 | $110.68M | +10.3% |
| Q2 FY2017 | Jun 30, 2017 | $110.19M | – |
| Q1 FY2017 | Mar 31, 2017 | $31.27M | – |
| Q4 FY2016 | Dec 31, 2016 | $100.76M | – |
| Q3 FY2016 | Sep 30, 2016 | $100.32M | – |
See a number that looks wrong?